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Abstract 
When blood vessels are damaged, circulating platelets come into contact with activating stimuli that 
trigger aggregation and enable them to form a haemostatic plug. This process is subject to both 
positive and negative feedback to ensure that platelets respond appropriately to damage and do not 
form thrombi that totally occlude the vessel. Dysregulation of negative feedback mechanisms is 
believed to contribute to the increased risk of thrombosis associated with some diseases. Despite the 
association with thrombosis, platelet derived negative regulators of platelet activation are relatively 
poorly understood in comparison to mediators of platelet activation. However, it is increasingly 
apparent that the mechanisms by which platelets restrain activation are diverse and of equal 
complexity to those that mediate positive signalling. Some regulators, such as RASA3 and JAM-A, act 
as gatekeepers that must be deactivated for platelet activation to occur. In contrast, regulators that 
contain ITIMs, such as PECAM-1, are activated following stimulation and mediate negative regulation 
via phosphatases that restrain activation. Wnt3a and ESAM are thought to directly limit platelet-
platelet adhesion by blocking activation of the fibrinogen receptor, integrin αIIbβ3. The various 
isoforms of PKC expressed by platelets provide a diverse and complex array of inhibitory effects 
including receptor desensitisation. Many platelet derived inhibitors have been identified but not fully 
characterised and so questions remain regarding the mechanisms that underlie their effects on 
platelet activity following their activation, inhibition or genetic disruption. In this chapter the current 
understanding and recent developments in the field of platelet-derived inhibitors of platelet 
activation will be discussed.  
 
  
Introduction 
Negative regulators of platelet activation are a relatively unexplored aspect of platelet physiology yet 
have an important role in tempering thrombus development by contributing much needed negative 
regulation to a process that is amplified by several positive feedback mechanisms. Some negative 
regulators, such as RASA3 and JAM-A, act as gate keepers that modulate key mediators of activation 
and provide barriers that must be deactivated to permit full activation and stable thrombus 
formation. Other negative regulators, such as PECAM-1 and other proteins that signal through ITIMs, 
come into play once platelets are activated and provide restraining, negative feedback for activatory 
pathways. Many platelet-derived inhibitors have been identified but not fully characterised and so 
questions remain regarding the mechanisms that underlie the effects on platelet activity following 
their activation, inhibition or genetic disruption. However, dysregulation of inhibitory signals is 
believed to contribute to enhanced risk of thrombosis in diseases such as diabetes and other 
pathological conditions. In this chapter we have described platelet-derived inhibitors of platelet 
function that are secreted by or expressed within platelets themselves to provide inhibition or 
negative regulation to the processes that underpin activation.  
ITIM signaling 
Immunoreceptor tyrosine-based inhibitory motif (ITIM) containing receptors are capable, following 
ligand binding, of triggering cell signalling mechanisms that counteract activation processes. The ITIM 
consensus sequence L/I/V/S-x-Y-x-x-L/V usually found in the cytoplasmic tail has been identified in 
several proteins that are expressed in platelets, including PECAM-1, CEACAM, G6b-B, and LILRB2/PIRB 
which are associated with the negative regulation of platelet activation (Wu and Lian, 1997, Cicmil et 
al., 2000, Jones et al., 2001, Wong et al., 2009, Alshahrani et al., 2014, Yip et al., 2015, Newland et al., 
2007, Mori et al., 2008, Coxon et al., 2012). When ITIM-bearing receptors bind their ligand, the 
receptors cluster and src family kinases phosphorylate the tyrosine residues in the ITIM motif. The 
phosphorylated ITIM is then able to recruit negative regulators including phosphatases such as 
SHP1/SHP2 (Kharitonenkov et al., 1997) and SHIP1/SHIP2 (Bruhns et al., 2000). The recruited 
phosphatases are localised within close proximity to their substrates, which allows them to inactivate 
molecules involved in activatory cell signaling including tyrosine kinases and phosphatidylinositol 
3,4,5-trisphosphate kinase (PI3K) (Figure 1). ITIMs were initially considered to be the ‘off switch’ that 
counteracts the positive signaling initiated by ITAM (consensus sequence Yxx(L/I)x6-12Yxx(L/I)) 
containing receptors such as the GPVI receptor complex. However, studies have now identified 
negative regulation of GPCR signaling by PECAM-1 and G6b-B that are independent of ITAM signaling 
pathways (Newland et al., 2007, Jones et al., 2009) (Figure 1).  
PECAM-1 
Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a 130kDa member of the Immunoglobulin 
superfamily that is expressed on several haematopoetic cells including platelets, monocytes, 
neutrophils, some types of T cells and endothelial cells and is associated with several biological 
processes including negative regulation of platelet activation (Newman, 1997). PECAM-1 contains a  
574 amino acid extracellular domain that is composed of 6 Ig-like homolog and mediates homophillic 
interactions with other PECAM-1 molecules. It also contains a short 19 amino acid single 
transmembrane spanning domain and a 118 amino acid cytoplasmic domain that includes the ITIM 
(Sun et al., 1996, Newton et al., 1997, Goyert et al., 1986, Lyons et al., 1988). Expression levels of 
PECAM-1 are variable with copy numbers ranging between 5,000- 20,000 present at the cell surface 
per platelet (Jones et al., 2009). PECAM-1 is present in platelet α-granules, resulting in an increase in 
cell surface expression following platelet activation and granule secretion (Hidari et al., 1997, Wu and 
Lian, 1997, Metzelaar et al., 1991, Jones et al., 2009). PECAM-1 is believed to be activated by 
homomeric clustering (Thai le et al., 2003) but interactions with other receptors have also been 
reported (Buckley et al., 1996). Clustering of PECAM-1 to ITAM containing receptors or ligation of 
PECAM-1 using anti-PECAM-1 antibodies or recombinant human PECAM-1 immunoglobulin chimeras, 
has been shown to inhibit GPVI, GPIb and GPCR-stimulated platelet aggregation. Activation of PECAM-
1 has broad effects on signal transduction, including reduced total tyrosine phosphorylation, inositol 
tris-phosphate production, Ca2+ mobilisation and granule secretion which underpins a reduction in 
thrombus formation (Cicmil et al., 2002, Jones et al., 2009, Jones et al., 2001, Thai et al., 2003, 
Rathore et al., 2003). PECAM-1-/- platelets exhibit hyper-reactivity when stimulated with low 
concentrations of collagen and CRP but not thrombin, ADP or PAR receptor agonists. Studies that 
have measured  thrombus formation ex vivo and  in vivo using mice deficient in PECAM-1 indicate an 
inhibitory role for PECAM-1 in the regulation of thrombus formation, as increased thrombus size and 
stability is observed (Falati et al., 2006).  
PECAM-1 is regulated by phosphorylation of its cytoplasmic tail at the tyrosine residues Y663 and 
Y686 within the ITIM and ITSM (immunoreceptor tyrosine-based switch motif) motifs. PECAM-1 is 
constitutively phosphorylated at low levels in resting platelets and phosphorylation is increased 
following anti-PECAM-1 antibody induced crosslinking, but also in response to several platelet 
agonists including collagen, convulxin, thrombin and GPIb agonists suggesting, that PECAM1 provides 
a negative feedback mechanism to control the level of platelet activation and thrombus formation 
(Jackson et al., 1997, Modderman et al., 1994, Cicmil et al., 2000, Jones et al., 2001, Rathore et al., 
2003). Phosphorylation of PECAM-1 at the ITIM is mediated by activation of Src family kinases and 
Fyn, Lyn, Src, Yes and Hck have all been shown to coimmunoprecipitate with PECAM-1 (Cao et al., 
1998, Cicmil et al., 2000).  Phosphorylated ITIMs provide a binding and activation platform for SH2 
domain containing proteins, including phosphatases SHP-1 and SHP-2, SHIP1 and PP2A (Pumphrey et 
al., 1999, Relou et al., 2003, Henshall et al., 2001) that are associated with the negative regulation of 
platelet activity. Following activation of GPVI signaling PI3K associates with the LAT signalosome which 
is located in lipid rafts that are enriched with the phosphoinositide substrates of PI3K. In contrast to 
LAT, the majority of PECAM-1 molecules are excluded from lipid rafts. Following crosslinking of 
PECAM-1, SHP2 is recruited to PECAM-1 and associates with PI3K, relocalising PI3K away from lipid 
rafts and the LAT signalosome, preventing association with and activation of PI3K (Moraes et al., 
2010a). Most recently the mechanism by which PECAM-1 negatively regulates responses to non-GPVI 
agonists such as thrombin and VWF has also been described (Jones et al., 2014). PECAM-1 inhibits 
fibrinogen binding and secretion stimulated by thrombin but not PAR1 and PAR4 activating peptides, 
which suggests that PECAM-1 has a role in regulating  GPIbα, a receptor that recruits thrombin to the 
platelet plasma membrane facilitating stimulation of PARs (Jones et al., 2012). PECAM-1 was found to 
mediate the internalisation of GPIbα in platelets through dual AKT /glycogen synthase kinase-
3/dynamin-dependent and αIIbβ3-dependent mechanisms. 
A study looking at the expression patterns of PECAM-1 in platelets has identified that expression 
levels of PECAM-1 are variable within the human population with approximately 5,000- 20,000 copies 
estimated to be present at the cell surface. Analysis of the relationship between receptor expression 
levels and platelet responsiveness to platelet agonists, revealed an inverse relationship between 
levels of PECAM-1 expression and platelet response to stimulation by CRP-XL and ADP (Jones et al., 
2009). Although the association is described as modest accounting for 6-10% of total variability in 
responses, this was at a similar level of magnitude to that observed for the positive correlation of 
GPVI or αIIbβ3 expression levels with platelet responsiveness.   
Despite the overall negative role for PECAM-1 in the regulation of platelet activity, PECAM-1 signaling 
in other cell types is associated with the regulation of integrin function, whereby crosslinking of 
PECAM-1 enhances adhesion mediated by integrins (Tanaka et al., 1992, Piali et al., 1993, Leavesley et 
al., 1994, Berman et al., 1996, Varon et al., 1998, Chiba et al., 1999, Zhao and Newman, 2001). Studies 
in human platelets have shown that antibody crosslinking  of PECAM-1 enhances adhesion and 
spreading on fibrinogen (Zhao and Newman, 2001) indicating a positive role for PECAM-1 in the 
regulation of integrin αIIbβ3. Mouse platelets deficient in PECAM-1  show impaired spreading and 
adhesion on fibrinogen, clot retraction and phosphorylation of focal adhesion kinase, suggesting a 
defect in integrin αIIbβ3 outside-in signalling (Wee and Jackson, 2005).  It has been hypothesised that a 
dual role for PECAM-1 could therefore exist, in which it initially functions to suppress platelet 
activation but once platelets are strongly activated, PECAM-1 positively regulates functions mediated 
by integrin outside-in signaling (Jones et al., 2012).  
High cholesterol significantly increases an individual’s risk of atherosclerosis, coronary heart disease, 
heart attacks and stroke. Statins are widely prescribed as cholesterol lowering drugs and have been 
shown to reduce platelet activation. It has been described that one possible mechanism by which 
statins inhibit platelet function is through the activation and regulation of PECAM-1 (Moraes et al., 
2013). Treatment of platelets with statin simvastatin showed simvastatin was capable of increasing 
PECAM-1 phosphorylation and recruitment of SHP-2 to the ITIM which is essential for the negative 
function of PECAM-1. In further support of statins working through PECAM-1, PECAM-1 deficient mice 
showed reduced sensitivity to statins compared to WT controls indicating that they must in some way 
work via PECAM-1.   
CEACAM-1 and CEACAM-2 
Carcinoembryonic antigen (CEA)-related cell adhesion molecules, CEACAM1 and CEACAM2 are ITIM 
containing membrane receptors that are expressed in both human and mouse platelets. CEACAM1 
and 2 both contain extracellular glycosylated Ig-domains (four in CEACAM1 and two in CEACAM2), a 
transmembrane domain and a long cytoplasmic tail that contains the ITIM which is almost identical 
between the two proteins (Salaheldeen et al., 2012). CEACAM1 is activated following clustering via a 
homophillic interaction . The endogenous ligand of CEACAM2 has not yet been identified but can be 
activated by the murine coronavirus mouse hepatitis virus spike glycoprotein(s) (Robitaille et al., 
1999). Studies using other cell types including T-cells and epithelial cells (Nagaishi et al., 2006) have 
shown that CEACAM1 and CEACAM2 use their ITIMs to recruit SHP1 and, to a lesser degree, SHP2 
which can then initiate negative regulation of positive signaling pathways (Beauchemin et al., 1997).   
Mice deficient in either CEACAM1 or CEACAM-2 show increased adhesion to fibrillar collagen and 
increased aggregation and secretion evoked by GPVI  which indicates a role for both receptors in the 
negative regulation of GPVI signaling and platelet responses (Wong et al., 2009, Alshahrani et al., 
2014). CEACAM2 deficient platelets have also been shown to have increased platelet responses to 
CLEC-2 agonist Rhodocytin. Platelets deficient in either CEACAM-1 or CEACAM-2 show increased 
tyrosine phosphorylation of Syk and PLCγ2 following stimulation by CRP and also Rhodocytin in 
CEACAM2-/- platelets. Platelets from mice deficient in either CEACAM1 or CEACAM2 display increased 
thrombus growth in vitro and in vivo suggesting that CEACAM1 and 2, like PECAM1 are negative 
regulators of platelet GPVI signaling. Also similar to that observed with PECAM-1, it has been recently 
described that CEACAM1-/- platelets show reduced signaling and activation through αIIbβ3 suggesting 
an alternative, positive regulatory mechanism for CEACAM1 in platelets (Yip et al., 2015). The role of 
CEACAM2 in the regulation of integrin αIIbβ3 is as yet unknown .   
G6b-B 
The transmembrane protein G6b was identified through both proteomics and gene expression studies 
(Macaulay et al., 2007, Senis et al., 2007) and the G6b-B variant was confirmed to be present in 
platelets (Senis et al., 2007). G6b-B contains an extracellular domain consisting of 125 amino acids 
and a cytoplasmic tail that contains two ITIM sequences. The endogenous ligand of G6b-B has not yet 
been identified, but G6b-B has been shown to be constitutively phosphorylated in resting platelets, 
and this increases following stimulation with GPVI specific agonist collagen related peptide (CRP) or 
Thrombin (Senis et al., 2007). Treatment of cells expressing G6b-B with pervanadate to inhibit 
phosphatases enhances tyrosine phosphorylation of G6b-B and the recruitment of SHP1 and SHP2 (de 
Vet et al., 2001, Coxon et al., 2012), thereby suggesting that G6b-B works via a similar mechanism to 
other ITIM containing proteins to inhibit platelets.  Interestingly, studies using the DT40 cell line show 
that inhibition of GPVI signaling following G6b-B expression is retained in the absence of both SHP1 
and SHP2, and is also retained in the absence of SHIP suggesting redundancy between these 
phosphatases or the involvement of other inhibitory molecules and mechanisms of action (Mori et al., 
2008). Recent studies have identified that G6b-B is capable of interacting with several key signaling 
molecules, including Csk, Src, Fyn, Syk, PLCγ2 and PI3K, and it has been suggested that G6b-B may 
mediate its inhibitory effects on signaling and platelet activity by redistributing signaling molecules 
away from their substrates (Coxon et al., 2012). Further evidence of a negative regulatory role for 
G6b-B in platelets was found by using a crosslinking antibody for G6b-B which caused inhibition of 
platelet aggregation to CRP, and ADP. No alteration in ADP stimulated Ca2+ signaling was observed 
suggesting that G6b-B acts downstream of Ca2+ release. This suggests that G6b-B may act via an 
alternative inhibitory mechanism to that observed downstream of other ITIM containing receptors 
such as PECAM and CEACAM, where G6b-B is capable of inhibiting signaling events downstream of 
mobilisation of intracellular Ca2+ (Newland et al., 2007). However, G6b-B deficient mice do not show 
platelet hyper-reactivity, although this is likely to be attributed to an increase in GPVI receptor 
shedding, that is observed as a result of enhanced metalloproteinase production in the 
megakaryocytes of these mice (Mazharian et al., 2012). This indicates an important role for G6b-B in 
megakaryocytes but the physiological role of G6b-B in platelets remains unclear (Mazharian et al., 
2012).  
 
PIRB/LILRB 
The leukocyte immunoglobulin like receptors (LILRs) include two subfamilies, LILRA and LILRB, whilst 
the LILRA proteins contain an ITAM domain, the LILRB family members are characterised as containing 
an ITIM. Human platelets express LILRB2 and mouse platelets express its homolog PIRB which 
contains four cytoplasmic ITIMs (Takai, 2005). Platelets have also been found to express the PIRB 
ligand ANGPTL2, which is found in alpha granules, which may suggest that autocrine self- negative 
regulation of platelets via PIRB/LILRB2 following their activation may occur (Zheng et al., 2012, Fan et 
al., 2014). Recent studies have identified that treatment of platelets with purified ANGPTL2 results in 
an inhibition of their activation to several agonists including CRP, ADP and thrombin while adhesion 
and spreading on fibrinogen is also inhibited (Fan et al., 2014). PIRB-TM mutant mice, which are 
unable to mediate intracellular signalling through this receptor, have a hyper-reactive platelet 
phenotype with increased aggregation evoked by CRP, increased spreading on fibrinogen and 
increased clot retraction. Key GPVI signaling events following activation by CRP, including 
phosphorylation of LAT, SLP-76 and PLCγ2 are inhibited following ANGPTL2 treatment and increased 
in PIRB-TM mutants. During adhesion to fibrinogen, phosphorylation of FAK and β3 are also enhanced 
in PIRB-TM mouse platelets. PIRB dependent inhibition of GPVI and integrin αIIbβ3 signaling has been 
linked to the recruitment of SHP1 and SHP2 phosphatases, as both are recruited to PIRB and are 
phosphorylated following treatment with ANGPTL2 but their recruitment and phosphorylation is 
reduced in PIRB-TM expressing mice (Fan et al., 2014).  
 
Intracellular nuclear receptors 
Several intracellular nuclear receptors have been identified and characterised in human platelets 
including the peroxisome proliferator activating receptors (PPAR)s, PPARα, PPARβ/δ and PPARγ, the 
retinoid X receptor (RXR), liver X receptor (LXR), farnesoid X receptor (FXR) and Glucocorticoid 
receptor (GR) (Moraes et al., 2010c, Moraes et al., 2007, Spyridon et al., 2011, Moraes et al., 2005b, 
Ali et al., 2006a) (Figure 2).  
Peroxisome proliferator activated receptors 
PPARs represent three nuclear receptor isoforms, PPARα, PPARβ and PPARγ (Berry et al., 2003) which 
are involved in cell development, differentiation, cholesterol and fatty acid metabolism and glucose 
homeostasis (O’Brien et al., 2007, Barak et al., 1999, Kersten et al., 2000). All three isoforms of PPAR 
upon binding to their ligands are capable of heterodimerising with RXR another nuclear receptor and 
all have been identified to have acute non-genomic negative regulatory effects in human platelets.  
Treatment of platelets with ligands for PPARα, such as fenofibrate and statins were found to increase 
intracellular levels of cAMP resulting in inhibition of ADP-stimulated platelet activation. Fenofibrite 
was also found to inhibit platelet activation and increase bleeding time in WT mice but not mice 
deficient in PPARα-/- (Ali et al., 2009a). Following activation by fenofibrite, PPARα was found to 
associate with PKCα a key positive mediator of platelet activation, and it is thought that this 
interaction may in part contribute to the negative regulation of platelet activation that is observed 
following treatment with PPARα ligands.  
PPARβ/δ has been shown to decrease plaque formation and attenuate the progression of 
atherosclerosis (Lee et al., 2003). Studies using synthetic agonists for PPARβ/δ, GW0742 and L-165041 
have identified inhibitory actions for PPARβ/δ ligands on the mobilisation of intracellular Ca2+  and 
platelet aggregation following stimulation by ADP and other platelet agonists (Ali et al., 2006b). PGI2 a 
key inhibitory mediator of platelet function is also a ligand for PPARβ/δ and some of its inhibitory 
effects on platelet activity could be mediated through PPARβ/δ (Forman et al., 1997). As with PPARα, 
treatment of platelets with agonists of PPARβ/δ result in an increase in cAMP levels and PKCα has 
been identified as a potential binding partner of the receptor and a potential mechanism by which 
PPARβ/δ may regulate platelet reactivity (Ali et al., 2009b). 
Agonists of PPARγ, the thiazolidinediones are currently in use for the treatment of type 2 diabetes 
mellitus and have been observed clinically to have cardio-protective properties and reduce the risk of 
myocardial infarction (Dormandy et al., Sauer et al., 2006). The emerging role of PPARγ agonists as 
negative regulators of platelet function may provide a mechanistic basis for this observation. A clinical 
study that measured platelet function in patients with coronary heart disease treated with 
rosiglitazone reported long-term anti-platelet effects with down-regulation of p-selectin exposure and 
granule secretion in treated patients (Sidhu et al., 2004). Treatment of platelets ex vivo with the 
endogenous agonist of PPARγ, 15dPGJ2 or the synthetic agonist rosiglitazone results in reduced 
platelet responses including granule secretion and thromboxane B2 (TXB2) synthesis in response to 
thrombin or ADP (Akbiyik et al., 2004). Agonists of PPARγ have also been shown to suppress platelet 
activation stimulated by GPVI agonists, with platelet aggregation, granule secretion and mobilisation 
of intracellular Ca2+  inhibited following treatment with 15dPGJ2 (Moraes et al., 2010c). Treatment 
with PPARγ agonists results in reduced thrombus formation in vitro and in vivo (Moraes et al., 2010c, 
Li et al., 2005).  
Additionally statins, that are routinely prescribed as cholesterol lowering drugs have also been shown 
to activate PPARs (Ali et al., 2009a). Treatment of human whole blood with the statins, pravastatin, 
fluvastin and simvastin all resulted in a reduction in platelet aggregation to ADP. This decrease in 
platelet activity was attributed to a PPAR mediated increase in cAMP levels.     
RXR 
Human platelets and megakaryocytes express RXRα and RXRβ (Moraes et al., 2007). Treatment of 
platelets with the  endogenous agonist of RXR, 9-cis-retenoic acid or the synthetic agonist, 
methoprene acid , results in an inhibition of Gq protein coupled induced platelet aggregation that is 
stimulated by ADP and thromboxane A2 (TxA2). It is thought RXR regulates GPCR mediated platelet 
activation by binding to Gq in a ligand-dependent manner inhibiting Gq induced rac activation and 
intracellular Ca2+  release (Moraes et al., 2007). 
LXR  
The LXRα and LXRβ isoforms of LXR are implicated in the regulation of fatty acid, cholesterol and 
glucose homeostasis (Viennois et al., 2012, Viennois et al., 2011) and agonists for LXR have been 
described to have anti-inflammatory effects and be atheroprotective (Joseph et al., 2002, Tangirala et 
al., 2002).  LXRβ has been identified as the isoform present in platelets (Spyridon et al., 2011), and 
endogenous ligands for the LXR receptors include oxysterols (oxygenated derivatives of cholesterol) 
and several synthetic agonists including GW3965 and T0901317 also exist (Gabbi et al., 2014, 
Wójcicka et al., 2015). Treatment of platelets with synthetic agonist GW3965 results in inhibition of 
platelet activation, including aggregation, secretion and integrin activation stimulated by collagen, 
CRP or thrombin. GW3965-treated mice form smaller, less stable thrombi following laser injury of the 
cremaster arterioles. LXR has also been shown to interact with several components of the GPVI 
signaling pathway following treatment with GW3965, including Syk and PLCγ2, resulting in decreased 
phosphorylation and signaling (Spyridon et al., 2011, Moraes et al., 2010b).  
Glucocorticoid receptor 
The glucocorticoid receptor (GR) is activated by glucocortoid steroid hormones, a major class of anti-
inflammatory hormones, and prednisolone a synthetic derivative of cortisol that has been used to 
understand the role of GR in the regulation of platelet function. Platelets preincubated with 
prednisolone prior to agonist stimulation show reduced aggregation and TxB2 release in response to 
both ADP and TxA2 mimetic U46619 which could be reversed following treatment with a GR 
antagonist mifepristone (Moraes et al., 2005a).  However, the mechanism underlying negative 
regulation of platelet function by GR agonists is still poorly understood. 
 
Negative regulators of small GTPases and integrin αIIbβ3 activation 
One of the key processes that underpin thrombus formation is the activation of the integrin αIIbβ3. 
Activation of αIIbβ3 results in a conformational change in the receptor that enables fibrinogen binding 
and aggregation, and also initiates outside in signaling which sustains platelet activation. Suppression 
of integrin αIIbβ3 activation prevents inappropriate platelet aggregation and excessive thrombus 
formation that can cause vessel occlusion (Figure 3). 
RASA3 
RASA3 has recently been identified as an important inhibitor of integrin αIIbβ3 activation (Stefanini et 
al., 2015) through the regulation of RAP1b which is a critical regulator of integrin function in platelets 
(Chrzanowska-Wodnicka et al., 2005, Stefanini et al., 2012). Rap1b is positively regulated by the Ca2+-
sensing guanine exchange factor (GEF), CAlDAG-GEF1 (Crittenden et al., 2004) and RASA3 provides 
opposing, negative regulation that maintains platelets in a quiescent state when at resting [Ca2+]i 
(Stefanini et al., 2015). RASA3 deficiency is  embryonically lethal in mice but homozygous expression 
of a mutated form of RASA3 with impaired activity results in viable animals with platelet 
hyperreactivity that can be rescued by simultaneous deficiency of CALDAG-GEF1. However, integrin 
αIIbβ3 activation in the double knockout mouse occurs independently of P2Y12 and PI3K. 
JAM-A  
JAM-A is a transmembrane protein of the CTX family that is expressed on cell surface and has been 
identified in platelets. Mice deficient in JAM-A display increased aggregation to several platelet 
agonists, increased spreading on fibrinogen and clot retraction and increased thrombus formation 
indicating a role for JAM-A in the negative regulation of αIIbβ3 (Naik et al., 2012). JAM-A is 
phosphorylated in resting platelets and associates with αIIbβ3 (Naik et al., 2012). JAM-A is proposed to 
keep the integrin inactive by binding C-terminal src kinase (Csk) via its SH2 domain which recruits it to 
the integrin. Recruitment of Csk ensures that c-Src, which is associated with the integrin, remains in 
an inactive state through phosphorylation of the inhibitory Y529 in c-Src’s regulatory domain (Naik et 
al., 2014). On platelet activation JAM-A is dephosphorylated, Csk dissociates enabling activation of c-
Src and integrin αIIbβ3 activation.  
Studies using ApoE deficient mice that model high cholesterol and atherosclerosis, have highlighted 
the importance of the platelet inhibitory receptor JAM-A in the development of the pathological 
disease state. A recent study has shown that platelet deficiency in the inhibitory receptor JAM-A in 
ApoE-/- mice fed a high fat diet, increases aortic plaque formation and recruitment of inflammatory 
cells. Suggesting that platelet hyperreactivity such as that observed in JAM-A-/- platelets can 
contribute to atherosclerotic plaque formation (Karshovska et al., 2015).  
ESAM 
ESAM, a transmembrane glycoprotein, like JAM-A is a member of the CTX family and is also suggested 
to be involved in the negative regulation of adhesion and integrin αIIbβ3 outside-in signaling. In 
contrast to JAM-A, ESAM appears to negatively regulate integrin αIIbβ3 and limit its activity following 
platelet activation. ESAM is contained in the alpha granules and is translocated to the cell surface on 
activation (Nasdala et al., 2002). Mouse platelets deficient in ESAM show increased aggregation to 
GPCR agonists, inhibition of clot retraction,  increased thrombus formation in vivo  and reduced tail 
bleeding (Stalker et al., 2009). The mechanism by which ESAM functions is currently unknown, 
although interaction via its PDZ domain with NHERF-1, a scaffold protein highlights possible 
interaction with and regulation of several proteins, including GPCRs (Hall et al., 1998), G proteins and 
PLCβ (Rochdi et al., 2002) and components of the cytoskeleton (Shenolikar et al., 2004).  
Wnt3a 
Wnt3a is a glycoprotein that is released from endothelial cells (Goodwin et al., 2006) and also from 
TRAP stimulated platelets, enabling platelets to self-regulate and limit activation (Steele et al., 2009). 
Treatment of platelets with Wnt3a results in an inhibition of platelet adhesion and shape change, 
reduced dense granule secretion and reduced RhoA activation leading to diminished integrin αIIbβ3 
activation and aggregation. In platelets, Wnt3a is thought to exert its effects through activation of the 
canonical Wnt-β-catenin signaling pathway components of which also appear to be present in 
platelets (Semenov et al., 2007, Macdonald et al., 2007, Huang and He, 2008). In  other cell types β-
catenin has been shown to play a role in the regulation of cell adhesion, where it is involved in 
supporting the interaction of cadherins to the cytoskeleton (Huang and He, 2008). Negative 
regulation of platelet activation via Wnt3a signaling is thought to occur through regulation of small 
GTPase activity, including Rap1, Cdc42, Rac1, RhoA (Steele et al., 2012). It is thought that by favouring 
the GDP-bound state of Rap1 and Rho via the regulation of RAP1GAP and RhoA GTPase activity, whilst 
increasing levels of Cdc42 and Rac1 GTP levels, Wnt3a inhibits integrin αIIbβ3 adhesion and 
spreading. 
Neuropilin-1-plexin A complex 
Semaphorin 3A exists as a soluble covalently bound homodimer and is secreted by vascular 
endothelial cells (Serini et al., 2003). Semaphorin 3A negatively regulates platelet function through 
binding to the neuropilin-1- plexin A receptor complex which has been identified in platelets 
(Takahashi et al., 1999, Tamagnone et al., 1999, Kashiwagi et al., 2005). Semaphorin 3A treatment 
inhibits platelet function, possibly through regulation of integrin αIIbβ3 as activation of the integrin, 
aggregation and adhesion and spreading evoked by several platelet agonists are impaired.  The exact 
mechanisms by which Semaphorin 3A inhibits platelet function has not been fully elucidated, 
although inhibition of the GTPase Rac-1 appears to be a key regulatory step in the negative regulation 
of αIIbβ3 and cytoskeletal rearrangements (Kashiwagi et al., 2005).  
Cyclic nucleotide signaling 
Cyclic nucleotides cAMP and cGMP are well established inhibitors of platelet activation. Endothelium 
derived prostacyclin (PGI2) and nitric oxide (NO) activate the production of cAMP and cGMP 
respectively and play essential roles in keeping platelets in the resting state in the circulation.  The 
regulation of platelets by these molecules is discussed in detail in Chapter X. 
cAMP and Protein kinase A 
PGI2 binds to and activates the Prostaglandin receptor on the platelet surface (Dutta-Roy and Sinha, 
1987), which then propagates inhibitory signaling through the activation of Gs subunits which 
activates adenylyl cyclase and stimulates the production of cAMP from ATP (Gorman et al., 1977). 
cAMP activates cAMP dependent protein kinase A (PKA). Following platelet activation by agonists 
such as ADP and thrombin, adenylyl cyclase activity is inhibited and cAMP levels reduced through Gi 
signaling (Jantzen et al., 2001, Yang et al., 2002). PKA phosphorylates multiple target proteins that 
maintain platelets in an inactive resting state by limiting platelet activation. Several substrates of PKA 
have been well characterised and are linked to the negative regulation of platelets, including VASP 
which is involved in cytoskeletal rearrangements (Waldmann et al., 1987, Butt et al., 1994), inhibition 
of RapIb a key regulator of integrin αIIbβ3 affinity (Schultess et al., 2005, Miura et al., 1992), Inositol 
trisphosphate receptor (IP3R) which is involved in Ca2+ regulation (Cavallini et al., 1996) and the 
thromboxane A2 receptor (Reid and Kinsella, 2003). Other targets also include Gα13 (Manganello et 
al., 1999), GPIbβ (Wardell et al., 1989), and CALDAG-GEFI (Schultess et al., 2005)  
Recent studies have identified a cAMP independent mechanism of PKA activation following 
stimulation of platelets by thrombin or collagen (Gambaryan et al., 2010). In resting platelets a 
population of platelet PKA appears to be associated with NFκB-IκBα. Following stimulation by collagen 
or thrombin the catalytic subunit of PKA dissociates from NFκB-IκBα and is activated, enabling 
phosphorylation and activation of its substrates. This identifies an inhibitory feedback mechanism that  
prevents excessive platelet activation in response to stimuli (Gambaryan et al., 2010). 
Regulation of cGMP and PKG by Platelet-derived NO 
The cyclic nucleotide cGMP is a key negative regulator of platelet activation that inhibits platelets to 
keep them in the resting state in the healthy vasculature (Smolenski, 2012). Endothelial release of 
nitric oxide (NO) keeps platelets inactive by regulating their intracellular levels of cGMP (Mellion et al., 
1981, Radomski et al., 1987). Following the synthesis and release of NO from the healthy 
endothelium, NO crosses the platelet plasma membrane and binds to and activates, soluble guanyl 
cyclase (sGC), leading to the increased production of cGMP from GTP and activation of protein kinase 
G (PKG). Levels of cGMP are controlled by the phosphodiesterase, PDE5A which is present in platelets 
(Haslam et al., 1999). Platelets deficient in PKG are insensitive to cGMP-mediated inhibition of 
intracellular Ca2+ release (Eigenthaler et al., 1993) and PKG knock-out mice have a prothrombotic 
phenotype and exhibit increased intravascular adhesion and aggregation following ischaemia 
(Massberg et al., 1999). 
Platelets are also considered to be a source of NO. The mechanism by which platelets synthesise NO 
and whether or not it is of physiological importance is however, still an area of contention. Although 
NO itself is an established negative regulator of platelet function, the vascular endothelium has 
traditionally been considered the dominant source of NO within blood vessels. Platelets have been 
reported to express two nitric oxide synthase (NOS) isoforms, iNOS and eNOS but generate less NO 
than endothelial cells (Radomski et al., 1990b) although the presence of eNOS is contentious 
(Gambaryan et al., 2008). Studies into the effects of platelet-derived NO on platelet function using 
iNOS/eNOS knockout mice have more recently suggested eNOS it is not a major regulator of platelet 
function (Gambaryan et al., 2008, Tymvios et al., 2009). There is evidence that platelets can produce 
NO from nitrate although further research is needed to understand the mechanism (Apostoli et al., 
2014). Platelet NO production is inducible and is mediated by Ca2+ elevation (Radomski et al., 1990b) 
and is therefore stimulated by many platelet agonists such as ADP and arachidonic acid. However, the 
question of whether platelet-derived NO can inhibit platelet aggregation is a source of debate 
(Gkaliagkousi et al., 2007) with some reports describing platelet-derived NO-mediated inhibition 
(Radomski et al., 1990b, Radomski et al., 1990a) and others reporting no effect (Thomas et al., 1990, 
Thompson et al., 1986).  
Defects in cAMP/cGMP signalling pathways have the potential to contribute to platelet 
hyperreactivity in cardiovascular disease including ischemic heart disease, heart failure and diabetes 
where the reduced sensitivity of platelets to the inhibitory effects of NO contributes to platelet 
hyperreactivity (Chirkov and Horowitz, 2007). Platelets from patients with type 2 diabetes mellitus 
and insulin insensitivity for example, are associated with reduced sensitivity of platelets to NO or 
prostacyclin and consequently greater levels of platelet reactivity. Removal of the negative inhibitory 
signal from these endothelial mediators, results in the failure to restrain the platelets activatory 
nature favouring platelet activation. Additionally a number of individuals with genetic abnormalities in 
prostacyclin signaling have reduce cAMP levels, resulting in hyperreactive platelets and a 
prothrombotic state, and defects in sGC function are linked to an increase prevelance of ischemic 
heart disease, heart failure and diabetes (Van Geet et al., 2009). In contrast patients with 
hypersensitivity to prostacyclin signaling, as a result of increased activity of Gs proteins show an 
increased risk of bleeding which is attributed to increased cAMP levels and an increased inhibition of 
platelet function (Van Geet et al., 2009). It is also suggested that in patients with obesity in addition to 
defects in sGC function, cAMP synthesis may also be altered and defects in downstream effectors of 
cAMP and cGMP signaling may contribute to platelet hyperreactivity (Russo et al., 2010).  
Other mechanisms of platelet inhibition 
Phosphatases 
Protein modification by phosphorylation is a key mechanism of signal transduction in platelets. 
Phosphorylation is a reversible post-translational modification that enables regulation of signal 
transduction and platelet function by phosphatase dependent dephosphorylation of key signaling 
proteins. Phosphatases are key mediators of several negative signaling pathways in platelets such as 
those exhibited by the ITIM containing receptors. Protein tyrosine phosphatases such as SHP1 and 
SHP2, SHIP1 and SHIP2, PP2, PTEN and TULA2 have well established roles in the negative regulation of 
platelet signaling, in general negatively regulating receptor proximal signaling events leading to 
reduced mobilisation of Ca2+, granule secretion and integrin activation (Senis, 2013). SHP2 is well 
established for its roles in the negative regulation of platelet signaling events downstream of the 
majority of platelet agonists, including GPVI and GPCRs (Ma et al., 2012, Jackson et al., 1997). These 
observations are supported by studies using mouse platelets deficient in SHP2 which show enhanced 
activation to fibrinogen (Mazharian et al., 2013). The histidine phosphatase TULA, dephosphorylates 
and inactivates Syk preventing further downstream signaling (Thomas et al., 2010). TULA deficient 
mice platelets show increased hyperreactivity to GPVI agonists, and also increased thrombus 
formation and reduced bleeding times. The phosphoinositide phosphatases SHIP-1 and PTEN are 
involved in the regulation of PI3-kinase function through alteration of the phosphoinositol cycle 
(Laurent et al., 2014). PTEN-deficient platelets which show hyper-responsiveness to collagen, exhibit 
increased PI3K activity and show reduced bleeding times in vivo. Finally the serine/threonine kinase 
phosphatase PP2A is involved in the negative regulation of integrin αIIbβ3 function and signaling 
(Pradhan et al., 2010, Gushiken et al., 2008). PP2A mediates dephosphorylation of PKCζ and PTP-1B 
which reduces Src phosphorylation and activation (Mayanglambam et al., 2011, Pradhan et al., 2010, 
Gushiken et al., 2008). It is important to note, however, that whilst several phosphatases are 
associated with negative regulation of platelet function, many positive regulatory functions for 
phosphatases have been identified in platelets (Senis, 2013). 
Receptor desensitisation 
Platelets can regulate and limit their responsiveness to platelet agonists, through desensitisation of 
their receptors following agonist stimulation. ADP for example is a critical secondary mediator of 
platelet signaling, yet despite this it has been shown that platelets desensitise following continued 
exposure to ADP (Mundell et al., 2006, Hardy et al., 2005, Cunningham et al., 2013). This diminished 
response is attributed to desensitisation of both the P2Y1 and P2Y12 receptors via agonist mediated 
internalisation of each receptor. Studies using both platelets and 1321N1 cells have identified that the 
P2Y1 and P2Y12 receptors are desensitised by different mechanisms following platelet agonist 
stimulation.  Desensitisation of the P2Y1 receptor is mediated by both classical and novel isoforms of 
protein kinase C (PKC), whilst P2Y12 desensitisation is mediated by G protein coupled receptor kinase 
and the novel isoforms of PKC (Hardy et al., 2005). 
PKC isoforms 
Protein kinase C (PKC), a family of serine/threonine kinases regulate many aspects of platelet 
signaling. The different isoforms of PKC are classified into three different subtypes classical, novel and 
atypical isoforms, according to their structure and mechanism of regulation. Several isoforms have 
been identified in human platelets although expression of some isoforms is controversial (Newton, 
1997, Mellor and Parker, 1998, Murugappan et al., 2004, Buensuceso et al., 2005, Hall et al., 2008, 
Pears et al., 2008, Konopatskaya et al., 2009, Bynagari et al., 2009, Nagy et al., 2009, Harper and 
Poole, 2010). Historically the PKC family were considered to play an overall positive role in the 
regulation of platelet activity, as broad spectrum PKC inhibitors were shown to inhibit granule 
secretion, TxA2 synthesis, integrin activation, aggregation and thrombus formation (Harper and Poole, 
2010). However, negative regulatory roles have subsequently also been identified for the PKC family. 
Studies using broad spectrum inhibitors have also identified negative roles in the regulation of 
receptor desensitisation (see section on receptor desensitisation) and Ca2+ release, and studies using 
isoform specific deficient mice have identified negative regulatory roles for the novel isoforms PKCδ 
and PKCθ (Harper and Poole, 2010).  
Transgenic mice deficient in PKCδ have identified a negative regulatory role for PKCδ in the regulation 
of integrin αIIbβ3 outside-in signaling and filopodia formation on fibrinogen due to an interaction 
between PKCδ and VASP (Pula et al., 2006). PKCδ has also been shown to negatively regulate GPVI 
induced platelet responses, as platelets from PKCδ deficient mice have enhanced aggregation and 
dense granule secretion in comparison to WT controls. This was also confirmed in human platelets 
using a cell permeable peptide that is designed to block the interaction of PKCδ and its RACK, δ(V1-1)-
TAT (Chari et al., 2009). Contrasting reports however, also exist as other groups found no abnormality 
in GPVI-dependent dense granule secretion in PKCδ−/− platelets (Pula et al., 2006). PKCδ deficient 
platelets generate larger thrombi when measured in vitro but not when measured in vivo (Gilio et al., 
2010, Chari et al., 2009). The overall role of PKCδ has therefore been difficult to define, possibly as a 
consequence of diverse positive and negative regulatory roles played by this PKC isoform. 
Studies that have utilised PKCθ isoform-specific inhibitors have identified negative roles for PKCθ in 
several processes in GPVI-induced platelet activation, including aggregation, α-granule secretion, 
αIIbβ3 activation and changes in intracellular Ca2+  levels,  as all were increased following treatment of 
platelets with the inhibitor. Studies that have utilised PKCθ deficient mice have generated conflicting 
reports of both positive and negative roles in the regulation of platelet activation (Hall et al., 2008, 
Nagy et al., 2009, Harper and Poole, 2009, Cohen et al., 2011, Unsworth et al., 2012, Harper and 
Poole, 2010, Gilio et al., 2010). These differences have been attributed to different experimental 
conditions  whereby PKCθ may have a negative role following exposure to low agonist concentrations, 
and a positive role following exposure to higher concentrations of platelet agonists (Hall et al., 2008, 
Nagy et al., 2009, Cohen et al., 2011). 
Conclusion 
Platelet-derived mediators of negative regulation all function to limit or restrict platelet activation, yet 
are mechanistically diverse and affect pathways involved in many different processes (Figure 4). While 
many negative regulators have been identified, many of the processes that they regulate to achieve 
platelet inhibition are not yet fully characterised. However, it is becoming increasingly clear that  
negative regulatory mechanisms rival the complexity of the positive regulators of platelet activation. 
The key challenge in the field of inhibitory platelet signalling will be to establish the physiological and 
pathological importance of these proteins, their potential as drug targets and their role in 
determining disease risk. 
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Figure 1. ITIM Signaling 
When ITIM-bearing receptors bind their ligand they cluster and the ITIM domains are phosphorylated. 
The phosphorylated ITIM domains recruit phosphastases through their SH2 domains, bringing them 
into close proximity with their substrates. The phosphatases SHP1/2 and SHIP1/2 dephosphorylate 
PI3K, LAT and PLCγ2 and other molecules in the signaling pathways evoked by ITAM containing / 
linked receptors, such as GPVI, causing inactivation and contributing to negative regulation. The 
phosphatases recruited by ITIMs are also able to negatively regulate PI3K downstream of GPCRs, 
contributing negative regulation to non-ITAM signaling pathways. 
Figure 2. Intracellular nuclear receptor signaling.  
Several intracellular nuclear receptors have been identified and characterised in human platelets 
including the peroxisome proliferator activating receptors (PPAR)s, PPARα, PPARβ/δ and PPARγ, the 
retinoid X receptor (RXR), liver X receptor (LXR), farnesoid X receptor (FXR) and Glucocorticoid 
receptor (GR). The nuclear receptors are believed to negatively regulate platelet activity through 
various mechanisms following activation by their ligands, although these mechanisms are not well 
characterised. Both PPARα and PPARβ/δ are thought to negatively regulate platelet function through 
regulation of cAMP levels, whilst PPARγ and LXR receptors interact with and inhibit components of 
early GPVI signaling. In contrast RXR and GR appear to inhibit Gq signaling events. Grey lines 
represent platelet agonist signaling and black arrows represent the pathways or proteins that are 
modulated by nuclear receptor agonists in platelets. 
Figure 3. Negative regulators of small GTPases and integrin αIIbβ3 
RASA3 inhibits RAPIb, preventing signal transduction that enables integrin αIIbβ3 activation until PI3K 
activation downstream of Gi-coupled P2Y12 inhibits RASA3. Wnt 3a activates the β-catenin signaling 
pathway that negatively regulates small GTPases including Rac1 and Rap1 that underpin integrin 
activation. The neuropilin-1-plexin A complex is activated by semaphorin 3A which also negatively 
regulates Rac1. JAM-A inhibits c-Src-dependent integrin αIIbβ3 outside-in signaling through activation 
of Csk which negatively regulates c-Src. Stimulation with agonists causes dissociation of JAM-A from 
integrin αIIbβ3, reducing Csk activity and enabling activation of c-Src mediated integrin αIIbβ3 outside-in 
signaling. Semaphorin 3A is believed to activate the neuropilin-1 plexin A complex which inhibits Rac1 
causing inhibition of integrin αIIbβ3 activation. 
 
Figure 4. Platelet derived inhibitors of platelet function 
Well characterised activatory pathways (black) are regulated by multiple inhibitory pathways that 
regulate platelet responses to support their role in hemostasis. Receptors that signal through ITIMs 
(blue) recuits SHP1/2 and SHIP1/2 in close proximity to ITAM receptors where they de-phosphorylate 
components of activation pathways, inactivating them to provide negative regulation. Small GTPases 
regulate several important process in platelets such as granule secretion and integrin αIIbβ3 activation 
and so inhibitors of small GTPases (yellow) such as RASA3 and Wnt3a / β-catenin provide negative 
regulation for these key events. PKA and PKG are inhibitory kinases that are regulated by cyclic 
nucleotides (green), although these pathways are primarily regulated by non-platelet derived 
inhibitors they are also potentially regulated by platelet derived NO and non-cAMP dependent PKA 
activation. Other negative regulators (purple) such as phosphatases and kinases that regulate 
receptor desensitisation do not easily fit into discrete categories and mediate negative feedback via 
diverse mechanisms. 
 
